ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

This study investigates whether drugs that target the ALK gene mutation — called ALK tyrosine kinase inhibitors — can treat advanced squamous cell carcinoma (a type of cancer) in patients whose tumors test positive for ALK gene rearrangements. **You may be eligible if...** - You are 18 or older - You have advanced squamous cell carcinoma confirmed by biopsy or cytology, with no prior systemic treatment - Your tumor tests positive for an ALK gene fusion (by IHC, NGS, or FISH testing) - Your physical condition is good (ECOG performance status 0–1) - Your predicted survival is at least 12 weeks - You have measurable disease on scans and adequate organ function **You may NOT be eligible if...** - Your tumor does not test positive for ALK gene rearrangement - You have previously received systemic treatment for your cancer - You have active brain metastases, significant heart problems, or uncontrolled infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.